Kura Oncology, Inc. (NASDAQ:KURA) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Kura Oncology has received a consensus rating of "Moderate Buy" from 14 analysts, with three rating it as a hold, ten as buy, and one as strong buy.
• The stock's average 1-year price target is $24.10, despite recent downgrades from some brokerages, including a decrease in price target by Barclays from $32 to $11.
• For the most recent quarter, Kura Oncology reported an EPS of ( $0.75 ), significantly missing the consensus estimate of $0.15, with a revenue of $15.29 million compared to the expected $64.95 million.

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the fourteen research firms that are currently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $24.10.

A number of brokerages have commented on KURA. Wall Street Zen downgraded shares of Kura Oncology from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. Mizuho reduced their target price on shares of Kura Oncology from $32.00 to $30.00 and set an "outperform" rating for the company in a report on Monday, May 19th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Kura Oncology in a report on Thursday, June 26th. Barclays reduced their target price on shares of Kura Oncology from $32.00 to $11.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Finally, Wedbush restated an "outperform" rating and set a $36.00 price objective on shares of Kura Oncology in a report on Friday, June 20th.

Kura Oncology Trading Up 13.9%

NASDAQ KURA traded up $0.92 on Tuesday, hitting $7.52. 787,678 shares of the stock were exchanged, compared to its average volume of 1,404,055. The firm has a market capitalization of $652.48 million, a P/E ratio of -3.34 and a beta of 0.41. Kura Oncology has a 52-week low of $5.41 and a 52-week high of $21.57. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.16 and a current ratio of 6.16. The stock has a fifty day moving average price of $6.19 and a two-hundred day moving average price of $6.65.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by ($0.90). The firm had revenue of $15.29 million for the quarter, compared to analysts' expectations of $64.95 million. Research analysts forecast that Kura Oncology will post -2.44 EPS for the current fiscal year.

Institutional Trading of Kura Oncology

Hedge funds and other institutional investors have recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Kura Oncology in the 1st quarter worth $139,000. Rhumbline Advisers increased its stake in shares of Kura Oncology by 5.2% in the 1st quarter. Rhumbline Advisers now owns 105,206 shares of the company's stock worth $694,000 after acquiring an additional 5,215 shares during the last quarter. BNP Paribas Financial Markets increased its stake in shares of Kura Oncology by 969.9% in the 4th quarter. BNP Paribas Financial Markets now owns 163,559 shares of the company's stock worth $1,425,000 after acquiring an additional 148,272 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Kura Oncology by 7.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 131,718 shares of the company's stock worth $1,147,000 after acquiring an additional 9,050 shares during the last quarter. Finally, Ameriprise Financial Inc. acquired a new stake in shares of Kura Oncology in the 4th quarter worth $130,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.